0001209191-20-006279.txt : 20200204
0001209191-20-006279.hdr.sgml : 20200204
20200204161016
ACCESSION NUMBER: 0001209191-20-006279
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200131
FILED AS OF DATE: 20200204
DATE AS OF CHANGE: 20200204
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Arbuckle Stuart A
CENTRAL INDEX KEY: 0001557290
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 20573783
MAIL ADDRESS:
STREET 1: VERTEX PHARMACEUTICALS INCORPORATED
STREET 2: 130 WAVERLY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-01-31
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001557290
Arbuckle Stuart A
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
0
1
0
0
EVP, Chief Commercial Officer
Common Stock
2020-01-31
4
M
0
4692
187.53
A
37932
D
Common Stock
2020-01-31
4
S
0
4692
238.65
D
33240
D
Common Stock
2020-02-03
4
M
0
2156
91.05
D
35396
D
Common Stock
2020-02-03
4
M
0
1554
86.52
D
36950
D
Common Stock
2020-02-03
4
S
0
440
228.90
D
36510
D
Common Stock
2020-02-03
4
S
0
530
229.99
D
35980
D
Common Stock
2020-02-03
4
S
0
1300
231.16
D
34680
D
Common Stock
2020-02-03
4
S
0
900
231.87
D
33780
D
Common Stock
2020-02-03
4
S
0
540
232.71
D
33240
D
Common Stock
140
I
401(k)
Stock Option (Right to Buy)
187.53
2020-01-31
4
M
0
4692
0.00
D
2029-02-05
Common Stock
4692
20334
D
Stock Option (Right to Buy)
91.05
2020-02-03
4
M
0
2156
0.00
D
2026-02-01
Common Stock
2156
0
D
Stock Option (Right to Buy)
86.52
2020-02-03
4
M
0
1554
0.00
D
2027-02-02
Common Stock
1554
6213
D
Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $228.90 (range $228.37 to $229.11).
Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $229.99 (range $229.48 to $230.46).
Open market sales reported on this line occurred at a weighted average price of $231.16 (range $230.48 to $231.47).
Open market sales reported on this line occurred at a weighted average price of $231.87 (range $231.50 to $232.44).
Open market sales reported on this line occurred at a weighted average price of $232.71 (range $232.50 to $232.94).
The option vests in 16 quarterly installments from 02/06/2019.
Fully vested.
The option vests in 16 quarterly installments from 02/03/2017.
/s/ Omar White, Attorney-in-Fact
2020-02-04